Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Richard Bruggeman |
Documentos disponibles escritos por este autor (3)
Refinar búsqueda
Association between the 1291-c/g polymorphism in the adrenergic α-2a receptor and the metabolic syndrome / Arne J. Risselada en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)
[artículo]
Título : Association between the 1291-c/g polymorphism in the adrenergic α-2a receptor and the metabolic syndrome Tipo de documento: texto impreso Autores: Arne J. Risselada, Autor ; Jelle Vehof, Autor ; Richard Bruggeman, Autor Fecha de publicación: 2022 Artículo en la página: pp. 667-671 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: ADRA2A, Antipsicóticos, Síndrome metabólico, Esquizofrenia, 1291-C/G Resumen: The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. The strong interindividual differences in susceptibility to developing the metabolic syndrome suggests that the genetic makeup is a modulating factor. Part of the genetic puzzle can possibly be explained by variations in the gene coding for the adrenergic α-2a receptor (ADRA2A) because this receptor plays an important role in lipolysis. Link: ./index.php?lvl=notice_display&id=29413
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 667-671[artículo] Association between the 1291-c/g polymorphism in the adrenergic α-2a receptor and the metabolic syndrome [texto impreso] / Arne J. Risselada, Autor ; Jelle Vehof, Autor ; Richard Bruggeman, Autor . - 2022 . - pp. 667-671.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 667-671
Palabras clave: ADRA2A, Antipsicóticos, Síndrome metabólico, Esquizofrenia, 1291-C/G Resumen: The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. The strong interindividual differences in susceptibility to developing the metabolic syndrome suggests that the genetic makeup is a modulating factor. Part of the genetic puzzle can possibly be explained by variations in the gene coding for the adrenergic α-2a receptor (ADRA2A) because this receptor plays an important role in lipolysis. Link: ./index.php?lvl=notice_display&id=29413 Changing the obesogenic environment to improve cardiometabolic health in residential patients with a severe mental illness / Anne Looijmans en The British Journal of Psychiatry, Año 2017 - Vol. 211 - No. 5 (Noviembre)
[artículo]
Título : Changing the obesogenic environment to improve cardiometabolic health in residential patients with a severe mental illness : cluster randomised controlled trial Tipo de documento: texto impreso Autores: Anne Looijmans, Autor ; Annemarie P. M. Stiekema, Autor ; Richard Bruggeman, Autor Fecha de publicación: 2018 Artículo en la página: pp. 296-303 Idioma : Inglés (eng) Palabras clave: Enfermedad mental severa, Obesidad. Resumen: For patients with severe mental illness (SMI) in residential facilities, adopting a healthy lifestyle is hampered by the obesity promoting (obesogenic) environment. Link: ./index.php?lvl=notice_display&id=9757
in The British Journal of Psychiatry > Año 2017 - Vol. 211 - No. 5 (Noviembre) . - pp. 296-303[artículo] Changing the obesogenic environment to improve cardiometabolic health in residential patients with a severe mental illness : cluster randomised controlled trial [texto impreso] / Anne Looijmans, Autor ; Annemarie P. M. Stiekema, Autor ; Richard Bruggeman, Autor . - 2018 . - pp. 296-303.
Idioma : Inglés (eng)
in The British Journal of Psychiatry > Año 2017 - Vol. 211 - No. 5 (Noviembre) . - pp. 296-303
Palabras clave: Enfermedad mental severa, Obesidad. Resumen: For patients with severe mental illness (SMI) in residential facilities, adopting a healthy lifestyle is hampered by the obesity promoting (obesogenic) environment. Link: ./index.php?lvl=notice_display&id=9757 Predictors for starting depot administration of risperidone in chronic users of antipsychotics / Jelle Vehof en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 6 (Diciembre)
[artículo]
Título : Predictors for starting depot administration of risperidone in chronic users of antipsychotics Tipo de documento: texto impreso Autores: Jelle Vehof, Autor ; Maarten J. Postma, Autor ; Richard Bruggeman, Autor Fecha de publicación: 2023 Artículo en la página: pp. 625-630 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agentes antipsicóticos, Enfermedades de los ganglios basales, Antagonistas colinérgicos, Enfermedad crónica, Servicios de Farmacia Comunitaria, Inyecciones, Adherencia a la medicación, Risperidona, Esquizofrenia. Resumen: Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparisons involving RLAI in observational studies. Link: ./index.php?lvl=notice_display&id=30820
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 625-630[artículo] Predictors for starting depot administration of risperidone in chronic users of antipsychotics [texto impreso] / Jelle Vehof, Autor ; Maarten J. Postma, Autor ; Richard Bruggeman, Autor . - 2023 . - pp. 625-630.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 625-630
Palabras clave: Agentes antipsicóticos, Enfermedades de los ganglios basales, Antagonistas colinérgicos, Enfermedad crónica, Servicios de Farmacia Comunitaria, Inyecciones, Adherencia a la medicación, Risperidona, Esquizofrenia. Resumen: Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparisons involving RLAI in observational studies. Link: ./index.php?lvl=notice_display&id=30820